
Markku Sainio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3901461/publications.pdf Version: 2024-02-01



MARKEI SAINIO

#	Article	IF	CITATIONS
1	Solvent exposed occupations and risk of Parkinson disease in Finland. Clinical Parkinsonism & Related Disorders, 2021, 4, 100092.	0.5	5
2	Annoyance, perception, and physiological effects of wind turbine infrasound. Journal of the Acoustical Society of America, 2021, 149, 2238-2248.	0.5	12
3	Healthy people in healthy premises: the Finnish Indoor Air and Health Programme 2018–2028. Clinical and Translational Allergy, 2020, 10, 4.	1.4	8
4	Psychosocial treatments for employees with non-specific and persistent physical symptoms associated with indoor air: A randomised controlled trial with a one-year follow-up. Journal of Psychosomatic Research, 2020, 131, 109962.	1.2	4
5	Clinical Characteristics of Disability in Patients with Indoor Air–Related Environmental Intolerance. Safety and Health at Work, 2019, 10, 362-369.	0.3	11
6	Health-related quality among life of employees with persistent nonspecific indoor-air-associated health complaints. Journal of Psychosomatic Research, 2019, 122, 112-120.	1.2	7
7	Limitations of periodical health examinations in detecting occupational chronic solvent encephalopathy. Occupational and Environmental Medicine, 2019, 76, 688-693.	1.3	1
8	Work ability score of solvent-exposed workers. International Archives of Occupational and Environmental Health, 2018, 91, 559-569.	1.1	4
9	Prevalence of various environmental intolerances in a Swedish and Finnish general population. Environmental Research, 2018, 161, 220-228.	3.7	36
10	Prevalence of environmental annoyance in a Swedish and Finnish general population: Impact of everyday exposures on affect and behavior. Journal of Environmental Psychology, 2018, 56, 84-90.	2.3	3
11	1713aâ€Why isn't chronic solvent encephalopathy detected in periodical occupational health examinations. , 2018, , .		0
12	Building-Related Environmental Intolerance and Associated Health in the General Population. International Journal of Environmental Research and Public Health, 2018, 15, 2047.	1.2	16
13	Environmental Intolerance, Symptoms and Disability Among Fertile-Aged Women. International Journal of Environmental Research and Public Health, 2018, 15, 293.	1.2	15
14	Attention-Deficit/Hyperactivity Disorder and Fatal Accidents in Aviation Medicine. Aerospace Medicine and Human Performance, 2017, 88, 871-875.	0.2	7
15	Comparing cognitive-behavioural psychotherapy and psychoeducation for non-specific symptoms associated with indoor air: a randomised control trial protocol. BMJ Open, 2016, 6, e011003.	0.8	5
16	Reply to Letter to the Editor: Cognitive therapy in Sick Building Syndrome: Myths, beliefs or evidence. NeuroToxicology, 2016, 52, 186-187.	1.4	2
17	Neurotoxicity of solvents. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 131, 93-110.	1.0	19
18	Decreased work ability associated to indoor air problems – An intervention (RCT) to promote health behavior. NeuroToxicology, 2015, 49, 59-67.	1.4	18

Markku Sainio

#	Article	IF	CITATIONS
19	Solvent-induced encephalopathy in the Netherlands and Finland. Occupational Medicine, 2015, 65, 609-611.	0.8	4
20	Cervical and lumbar pain and radiological degeneration among fighter pilots: a systematic review and meta-analysis. Occupational and Environmental Medicine, 2015, 72, 145-150.	1.3	35
21	Cost of detecting a chronic solvent encephalopathy case by screening. NeuroToxicology, 2014, 45, 253-259.	1.4	8
22	Multimodal event-related potentials in occupational chronic solvent encephalopathy. NeuroToxicology, 2012, 33, 703-709.	1.4	5
23	Chronic solvent-induced encephalopathy: European consensus of neuropsychological characteristics, assessment, and guidelines for diagnostics. NeuroToxicology, 2012, 33, 710-726.	1.4	49
24	Chronic Solvent induced Encephalopathy: A step forward. NeuroToxicology, 2012, 33, 897-901.	1.4	4
25	Detecting chronic solvent encephalopathy in occupations at risk. NeuroToxicology, 2012, 33, 734-741.	1.4	19
26	Occupational chronic solvent encephalopathy in Finland 1995–2007: incidence and exposure. International Archives of Occupational and Environmental Health, 2010, 83, 703-712.	1.1	26
27	Symptom screening in detection of occupational solvent-related encephalopathy. International Archives of Occupational and Environmental Health, 2009, 82, 343-355.	1.1	26
28	Magnetic resonance imaging in occupational chronic solvent encephalopathy. International Archives of Occupational and Environmental Health, 2009, 82, 595-602.	1.1	20
29	Symptoms of chronic solvent encephalopathy: Euroquest questionnaire study. NeuroToxicology, 2009, 30, 1187-1194.	1.4	24
30	10th Congress of International Neurotoxicology Association. Human and Experimental Toxicology, 2007, 26, 147-148.	1.1	0
31	Colour vision defects in occupational chronic solvent encephalopathy. Human and Experimental Toxicology, 2007, 26, 375-384.	1.1	14
32	P300 of auditory event related potentials in occupational chronic solvent encephalopathy. NeuroToxicology, 2007, 28, 1230-1236.	1.4	7
33	Memory Performance Profile in Occupational Chronic Solvent Encephalopathy Suggests Working Memory Dysfunction. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1307-1326.	0.8	21
34	Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. NeuroToxicology, 2006, 27, 1013-1023.	1.4	5
35	Frequent loss of heterozygosity at 6q in pheochromocytoma. Human Pathology, 2006, 37, 749-754.	1.1	29
36	Identification of genetic aberrations on chromosome 22 outside theNF2locus in schwannomatosis and neurofibromatosis type 2. Human Mutation, 2005, 26, 540-549.	1.1	29

Markku Sainio

#	Article	IF	CITATIONS
37	Anosmia in association with occupational use of a waterproof coating chemical. Occupational Medicine, 2005, 55, 142-144.	0.8	6
38	Effects of long-term occupational solvent exposure on contrast sensitivity and performance in visual search. Environmental Toxicology and Pharmacology, 2005, 19, 497-504.	2.0	9
39	Solvent-related health effects among construction painters with decreasing exposure. American Journal of Industrial Medicine, 2004, 46, 627-636.	1.0	39
40	Loss of Heterozygosity at 6q Is Frequent and Concurrent with 3p Loss in Sporadic and Familial Capillary Hemangioblastomas. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1072-1079.	0.9	20
41	Stability of vocational outcome in adulthood after moderate to severe preschool brain injury. Journal of the International Neuropsychological Society, 2004, 10, 719-723.	1.2	50
42	Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors. Human Pathology, 2003, 34, 872-879.	1.1	26
43	Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncology Reports, 2002, 9, 955.	1.2	9
44	Recurrent DNA sequence copy losses on chromosomal arm 6q in capillary hemangioblastoma. Cancer Genetics and Cytogenetics, 2002, 133, 174-178.	1.0	19
45	High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282.	1.4	147
46	Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein. BBA - Proteins and Proteomics, 1998, 1387, 1-16.	2.1	48
47	Genomic structure of the human ezrin gene. Human Genetics, 1998, 103, 662-665.	1.8	12
48	Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?. Journal of Neurosurgery, 1998, 89, 36-41.	0.9	81
49	Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. Journal of Neurosurgery, 1997, 87, 610-614.	0.9	73
50	The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Current Opinion in Cell Biology, 1997, 9, 659-666.	2.6	191
51	Proliferative Potential of Sporadic and Neurofibromatosis 2-Associated Schwannomas as Studied by MIB-1 (Ki-67) and PCNA Labeling. Journal of Neuropathology and Experimental Neurology, 1995, 54, 776-782.	0.9	31